212 related articles for article (PubMed ID: 18829880)
1. Drug interactions and pharmacogenomics in the treatment of breast cancer and depression.
Henry NL; Stearns V; Flockhart DA; Hayes DF; Riba M
Am J Psychiatry; 2008 Oct; 165(10):1251-5. PubMed ID: 18829880
[No Abstract] [Full Text] [Related]
2. Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
Desmarais JE; Looper KJ
J Clin Psychiatry; 2009 Dec; 70(12):1688-97. PubMed ID: 20141708
[TBL] [Abstract][Full Text] [Related]
3. Selective serotonin reuptake inhibitors and adjuvant tamoxifen therapy: risk of breast cancer recurrence and mortality.
Cronin-Fenton D; Lash TL; Sørensen HT
Future Oncol; 2010 Jun; 6(6):877-80. PubMed ID: 20528223
[No Abstract] [Full Text] [Related]
4. Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6.
Appiani F; Carroll BT; Muñoz C; Trecco J
Ann Clin Psychiatry; 2011 May; 23(2):152-3. PubMed ID: 21547277
[No Abstract] [Full Text] [Related]
5. A hot flash on tamoxifen metabolism.
Goetz MP; Loprinzi CL
J Natl Cancer Inst; 2003 Dec; 95(23):1734-5. PubMed ID: 14652227
[No Abstract] [Full Text] [Related]
6. Antidepressants and tamoxifen. Drug interactions may increase risk of cancer recurrence or death.
Harv Ment Health Lett; 2010 Jun; 26(12):6-7. PubMed ID: 20669529
[No Abstract] [Full Text] [Related]
7. Treatment for hot flushes in women receiving tamoxifen.
Bydder SA; Spry NA
Med J Aust; 2002 Sep; 177(5):266. PubMed ID: 12197825
[No Abstract] [Full Text] [Related]
8. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment.
Jin Y; Desta Z; Stearns V; Ward B; Ho H; Lee KH; Skaar T; Storniolo AM; Li L; Araba A; Blanchard R; Nguyen A; Ullmer L; Hayden J; Lemler S; Weinshilboum RM; Rae JM; Hayes DF; Flockhart DA
J Natl Cancer Inst; 2005 Jan; 97(1):30-9. PubMed ID: 15632378
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen pharmacogenetics moves closer to reality.
Garber K
J Natl Cancer Inst; 2005 Mar; 97(6):412-3. PubMed ID: 15770000
[No Abstract] [Full Text] [Related]
10. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine.
Stearns V; Johnson MD; Rae JM; Morocho A; Novielli A; Bhargava P; Hayes DF; Desta Z; Flockhart DA
J Natl Cancer Inst; 2003 Dec; 95(23):1758-64. PubMed ID: 14652237
[TBL] [Abstract][Full Text] [Related]
11. Genetics examined in tamoxifen's effectiveness: recurrence warning urged for labeling.
Young D
Am J Health Syst Pharm; 2006 Dec; 63(23):2286, 2296. PubMed ID: 17105997
[No Abstract] [Full Text] [Related]
12. Successful duloxetine use to prevent venlafaxine withdrawal symptoms.
Hsiao MC; Liu CY
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):576. PubMed ID: 17889418
[No Abstract] [Full Text] [Related]
13. Biological perspectives. Serotonin and norepinephrine reuptake inhibitors (SNRIs): venlafaxine and duloxetine.
Lee SI; Keltner NL
Perspect Psychiatr Care; 2006 May; 42(2):144-8. PubMed ID: 16677140
[No Abstract] [Full Text] [Related]
14. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
Binkhorst L; Mathijssen RH; van Herk-Sukel MP; Bannink M; Jager A; Wiemer EA; van Gelder T
Breast Cancer Res Treat; 2013 Jun; 139(3):923-9. PubMed ID: 23760858
[TBL] [Abstract][Full Text] [Related]
15. Tamoxifen, antidepressants, and CYP2D6: the conundrum continues.
Holzman D
J Natl Cancer Inst; 2009 Oct; 101(20):1370-1. PubMed ID: 19797723
[No Abstract] [Full Text] [Related]
16. Menopausal symptoms following tamoxifen treatment for breast cancer.
Barton DL
Oncology (Williston Park); 2008 Apr; 22(4 Suppl Nurse Ed):46-8. PubMed ID: 19856564
[TBL] [Abstract][Full Text] [Related]
17. Serotonin toxicity in a CYP2D6 poor metabolizer, initially diagnosed as a drug-resistant major depression.
Gressier F; Ellul P; Dutech C; Ait Tayeb AEK; Monfort J; Corruble E; Becquemont L; Hardy P; Verstuyft C
Am J Psychiatry; 2014 Aug; 171(8):890. PubMed ID: 25082493
[No Abstract] [Full Text] [Related]
18. Severe tremor after cotrimoxazole-induced elevation of venlafaxine serum concentrations in a patient with major depressive disorder.
Geber C; Ostad Haji E; Schlicht K; Hiemke C; Tadić A
Ther Drug Monit; 2013 Jun; 35(3):279-82. PubMed ID: 23666577
[TBL] [Abstract][Full Text] [Related]
19. [Serotonin-noradrenaline reuptake inhibitors(SNRIs)].
Ishigooka J
Nihon Rinsho; 2001 Aug; 59(8):1523-9. PubMed ID: 11519152
[TBL] [Abstract][Full Text] [Related]
20. PharmGKB summary: venlafaxine pathway.
Sangkuhl K; Stingl JC; Turpeinen M; Altman RB; Klein TE
Pharmacogenet Genomics; 2014 Jan; 24(1):62-72. PubMed ID: 24128936
[No Abstract] [Full Text] [Related]
[Next] [New Search]
